Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlayne E Jackson

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
JAMA Neurology|January 14, 2020
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical TrialStuart H Isaacson, William Ondo, Carlayne E Jackson, et al.
Expert Review of Neurotherapeutics|August 30, 2023
Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral SclerosisGary L Pattee, Angela Genge, Philippe Couratier, et al.
Health and Quality of Life Outcomes|December 20, 2011
Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UKReza Sadjadi, Kelly A Vincent, Alison J Carr, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 9, 2008
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRSJeffrey Rosenfeld, Ruth M King, Carlayne E Jackson, et al.
Journal of Clinical Neuromuscular Disease|December 17, 2008
Primary lateral sclerosis: clinical and laboratory features in 25 patientsMike A Singer, Suleiman Kojan, Richard J Barohn, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
BMC Neurology|February 22, 2022
Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onsetHarper S Kim, John Son, Donghwan Lee, et al.
Muscle & Nerve|October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisGil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Muscle & Nerve|December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.
Journal of Medical Economics|March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALSPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
JAMA Neurology|January 14, 2020
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical TrialStuart H Isaacson, William Ondo, Carlayne E Jackson, et al.
Expert Review of Neurotherapeutics|August 30, 2023
Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral SclerosisGary L Pattee, Angela Genge, Philippe Couratier, et al.
Health and Quality of Life Outcomes|December 20, 2011
Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UKReza Sadjadi, Kelly A Vincent, Alison J Carr, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 9, 2008
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRSJeffrey Rosenfeld, Ruth M King, Carlayne E Jackson, et al.
Journal of Clinical Neuromuscular Disease|December 17, 2008
Primary lateral sclerosis: clinical and laboratory features in 25 patientsMike A Singer, Suleiman Kojan, Richard J Barohn, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 12, 2022
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trialPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
BMC Neurology|February 22, 2022
Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onsetHarper S Kim, John Son, Donghwan Lee, et al.
Muscle & Nerve|October 4, 2002
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisGil I Wolfe, Richard J Barohn, Barbara M Foster, et al.
Muscle & Nerve|December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatmentAngela Genge, Gary L Pattee, Gen Sobue, et al.
Journal of Medical Economics|March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALSPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Pageof 5